Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,087 recruiting studies in this area right now.
By phase
- Not applicable2,108
- Phase 21,118
- Phase 1824
- Phase 1/Phase 2483
- Phase 3349
- Phase 4127
- Phase 2/Phase 378
Top conditions
- Multiple Myeloma332
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease140
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia123
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema49
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center65
- City of Hope Medical Center61
- Mayo Clinic61
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California405
- Texas186
- Maryland149
- Alabama148
- Arizona124
- Florida111
- Massachusetts101
- New York98
- Ohio70
- Minnesota68
Recruiting studies5,087 total
- NCT04463316Recruiting
Clinic study for people with rare genetic conditions
This study is for people who have a rare syndrome or rare congenital condition and are seen at a rare-disease clinic. It aims to better understand these conditions and how care works in a team setting, which may help guide future treatment decisions.
Rotterdam, South HollandAges 18 years+ - NCT04466059Recruiting
AI tool for leukemia diagnosis using blood or marrow samples
This study tests whether an AI (computer system) can help improve leukemia and related blood cancer diagnoses. You may be able to help if your doctor is already evaluating you for a possible blood disorder and your sample is high enough quality for testing.
Munich, BavariaAges 18 years+ - NCT04469517Recruiting
Study of low-oxygen factors in hereditary bleeding disorder
This study looks at how “low-oxygen” signals may affect people with hereditary hemorrhagic telangiectasia (HHT), a genetic bleeding disorder. It may help researchers understand what drives symptoms and could guide future treatments.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT04477967Recruiting
Creating a liver transplant biobank for children
This trial sets up a long-term collection of medical information and samples from children who have had a liver transplant. It helps doctors study outcomes over time and improve care for future patients.
Chongqing, Chongqing MunicipalityAges 1 month–18 years - NCT04483206RecruitingPhase 1
Personalized stem cell transplant for multiple myeloma
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
Atlanta, GeorgiaAges 18 years+ - NCT04484012RecruitingPhase 2
CAR T cells plus acalabrutinib for mantle cell lymphoma
This trial tests whether modified immune cells (CD19 CAR T cells) given with the medicine acalabrutinib can help people with mantle cell lymphoma that has come back or did not respond. It may help by attacking lymphoma cells more strongly and improving disease control after prior treatment.
Duarte, CaliforniaAges 18–75 - NCT04493164RecruitingPhase 2
CPX-351 plus ivosidenib for IDH1-mutated leukemia or high-risk MDS
This trial tests CPX-351 together with ivosidenib in people with IDH1-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to improve disease control, especially in tumors with a specific genetic change called IDH1.
Houston, TexasAges 18 years+ - NCT04491370RecruitingPhase 1/Phase 2
Stem cell transplant then polatuzumab for certain lymphomas
This trial tests whether doing your own stem cell transplant, followed by polatuzumab, can improve outcomes in people with specific B-cell non-Hodgkin or Hodgkin lymphomas that did not fully respond or has come back. It aims to add a targeted medicine after transplant to help control the lymphoma.
Valhalla, New YorkAges 12–70 - NCT04494503RecruitingPhase 1/Phase 2
Study drug for hard-to-treat CLL or SLL after relapse
This Phase 1/2 study tests APG2575 alone or combined with other treatment in people whose CLL/SLL has come back or did not respond to prior therapy. The goal is to see how well the treatment works and how safe it is.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04496349RecruitingPhase 2
Study of two medicines for relapsed T-PLL or NHL
This trial tests APG-115 alone or with APG-2575 in adults whose T-PLL or NHL has come back or did not respond to treatment. It may help by targeting the cancer cells with a new drug approach when standard therapies have not worked.
Houston, TexasAges 18 years+ - NCT04501120RecruitingPhase 1/Phase 2
Study drug for relapsed AML and related blood cancers
This early-phase trial tests lisaftoclax, alone or with other medicines, in people whose acute leukemia has returned or did not respond to prior treatment. It aims to find out how well the treatment works and how safe it is, especially for patients who may not be able to take standard chemotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04506593Recruiting
GI Motility diagnosis registry for people with digestion movement problems
This trial is a registry, meaning it collects information about people being evaluated for problems with how the gut moves. It may help doctors better diagnose gastrointestinal motility disorders in the future.
Indianapolis, IndianaAges Any age - NCT04508790RecruitingPhase 2
Leflunomide plus pomalidomide with dexamethasone for relapsed myeloma
This trial studies whether a combination of three medicines (leflunomide, pomalidomide, and dexamethasone) can better treat multiple myeloma that has come back or stopped responding. It may help people who are not good candidates for transplant and who have measurable disease.
Duarte, CaliforniaAges 18 years+ - NCT04510766Recruiting
Test tumor genetic results to guide early trial treatments
This trial looks at your tumor’s genetic information from stored tissue to help match you to early-phase treatment options. It may help doctors find a therapy that fits your tumor, especially when standard options have limited benefit.
BellinzonaAges 18 years+ - NCT04512534RecruitingPhase 2
Check-in study of immunotherapy plus another drug for lymphoma
This Phase 2 trial tests whether combining sintilimab (an immunotherapy) with chidamide (an anticancer “epigenetic” drug) can shrink peripheral T-cell lymphoma that has come back or didn’t respond. It’s for adults who have measurable lymphoma spots and can safely take both medicines.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04512716RecruitingEarly Phase 1
Radioimmunotherapy then CD19 CAR T for hard-to-treat blood cancers
This early-phase study tests a two-step treatment: first a targeted radioactive antibody (131-I apamistamab) and then CD19 CAR T-cell therapy. It is for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) or diffuse large B-cell lymphoma (DLBCL) that is not responding or has come back, aiming to shrink cancer using engineered immune cells.
Basking Ridge, New JerseyAges 18 years+ - NCT04513639RecruitingPhase 2/Phase 3
Checking treatment for multiple myeloma after MRD becomes negative
This study looks at whether people with newly diagnosed multiple myeloma can safely continue or adjust treatment after they reach “MRD-negative,” meaning very low signs of disease in the bone marrow. It may help reduce the chance of relapse while avoiding unnecessary treatment for some patients.
ÅlesundAges 18–75 - NCT04518475RecruitingPhase 4
Eltrombopag with rituximab versus eltrombopag alone for ITP
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
TianjinAges 18–60 - NCT04524637Recruiting
Testing a clotting test in recent traumatic brain injury
This trial tests whether a special blood clotting test called thromboelastography can help assess clotting problems after a head injury. It may help doctors better understand bleeding risk and related complications early after trauma.
ShanghaiAges 18–80 - NCT04528355Recruiting
Study of hospital data after stem cell transplant for non-cancer illness
This study collects medical information from people with certain non-cancer conditions who receive a stem cell transplant. It may help doctors better understand transplant outcomes and care, since the study focuses on data collection rather than adding new treatment.
Pittsburgh, PennsylvaniaAges 2 months–60 years - NCT04532203RecruitingEarly Phase 1
CAR-T therapy for leukemia or lymphoma in the brain
This early-phase study tests CAR-T cells—immune cells engineered to recognize cancer—for people whose leukemia or lymphoma has spread to the central nervous system (the brain/spinal fluid). It may help shrink or control hard-to-treat (relapsed or refractory) cancers in the brain.
Hangzhou, ZhejiangAges 3–75 - NCT04532281RecruitingEarly Phase 1
CD19 CAR-T therapy for relapsed or resistant blood cancers
This early-phase study tests a treatment called CD19 CAR-T, made from your immune cells, for people whose CD19+ blood cancer has come back or did not respond. It may help your body better recognize and attack cancer cells, but eligibility is tight and the study is still early.
Hangzhou, ZhejiangAges Any age - NCT04532268RecruitingEarly Phase 1
CD19 CAR-T for relapsed or resistant B-cell blood cancers
This early-phase study tests “humanized” CD19 CAR-T therapy for people whose B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoma (NHL) has come back or didn’t respond. It’s designed to help the immune system recognize and attack cancer cells carrying the CD19 marker.
Hangzhou, ZhejiangAges 3–75 - NCT04533217Recruiting
Vertebroplasty for multiple myeloma back pain
This trial tests whether adding a procedure called vertebroplasty to usual care can better reduce back pain from multiple myeloma. It’s for people who have a small number of spine fractures in a specific area and significant pain.
Middelfart, Region SyddanmarkAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,087 recruiting hematology studies from the U.S. registry right now, out of 7,715 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.